TipRanks
First Trust NYSE Arca Biotechnology Index Fund Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh (BR:BFBI39)
:BFBI39
Brazil Market
BFBI39
First Trust NYSE Arca Biotechnology Index Fund Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh
RESEARCH TOOLSreports

Compare First Trust NYSE Arca Biotechnology Index Fund Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh (BFBI39) vs. Competitors

― Followers

Comparison Results

Name
Price
Market Cap
P/E Ratio
Yearly Gain
Analyst Consensus
Analyst Price Target
Compare
Top Analysts' Price Target
Smart Score
Follow
First Trust NYSE Arca Biotechnology Index Fund Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh
―
R$711.48M
―
26.58%
―
Global X Telemedicine & Digital Health ETF Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh
―
R$245.73M
―
0.00%
―
iShares Genomics Immunology and Healthcare ETF Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh
―
R$560.35M
―
47.52%
―
iShares US Pharmaceuticals ETF Shs Unsponsored Brazilian Depositary Receipt Repr 0.05555555 Sh
―
R$268.90M
―
22.31%
―
iShares US Medical Devices ETF Shs Unsponsored Brazilian Depositary Receipt Repr 0.0285714 Sh
―
R$524.85M
―
-18.47%
―
Biomm SA
―
R$1.00B
23.32
-35.76%
―

Performance Comparison

Ticker
Company Name
Price
Change
% Change
BR:BFBI39
First Trust NYSE Arca Biotechnology Index Fund Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh
64.68
13.75
26.99%
BR:BEDC39
Global X Telemedicine & Digital Health ETF Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh
30.87
0.00
0.00%
BR:BIDN39
iShares Genomics Immunology and Healthcare ETF Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh
73.73
14.79
25.10%
BR:BIHE39
iShares US Pharmaceuticals ETF Shs Unsponsored Brazilian Depositary Receipt Repr 0.05555555 Sh
27.30
5.26
23.88%
BR:BIHI39
iShares US Medical Devices ETF Shs Unsponsored Brazilian Depositary Receipt Repr 0.0285714 Sh
7.59
-1.69
-18.25%
BR:BIOM3
Biomm SA
6.61
-3.65
-35.56%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts